Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Glaxosmithkline Plc LSE:GSK London Ordinary Share GB0009252882 ORD 25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -3.80 -0.25% 1,489.40 1,491.80 1,492.80 1,507.00 1,469.80 1,496.00 8,590,242 16:35:03
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 33,754.0 6,221.0 93.9 15.9 74,724

Glaxosmithkline Share Discussion Threads

Showing 19026 to 19049 of 21100 messages
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
DateSubjectAuthorDiscuss
31/1/2019
08:10
Monty...this is bad for top and bottom line. The clock is now ticking . Pity they did not cut dividend a few years ago.
zicopele
31/1/2019
08:06
Not has if news came out the blue, ok GSK drop their price and will compete. I would rather have a trusted brand for the same money than a generic version.
montyhedge
30/1/2019
23:17
Oh dear....Mylan has just been given FDA approval for Advair generic. Mylan is up 7% and has added $1bn to its market capitalisation. That market cap must come from.GSK. I reckon a down day tomorrow, down more than 1%
zicopele
30/1/2019
17:00
"zicopele 30 Jan '19 - 11:53 - 19002 of 19005 0 0 0 How is a breakup a solution to debt? Debt has to be repaid. Solution to debt is drug discoveries and that may include reducing dividend. Hopefully Tesaro will be successful as acquisition" Break up as in demerger I suspect of remaining business. Pack the majority of the debt on the segment with most regular cashflow able to service such and then see that segment sold to another Phamraceutucal company.. Remaining stand alone segment relatively debt fre, debt now another Pahrm Cos problem..
wbecki
30/1/2019
13:31
Sector rotation starting to take place. The pharmas should have a good run for a while. GSK and AZN powering ahead.
fuji99
30/1/2019
12:42
If there is any CGT payable as a result of presumed sale, that represents value destruction. A demerger has been intimated but debt is debt. New drugs are the solution.
zicopele
30/1/2019
11:57
Presumably they believe that a breakup would be by a sale, rather than a share distribution. The proceeds used to pay off debt.
alphorn
30/1/2019
11:53
How is a breakup a solution to debt? Debt has to be repaid. Solution to debt is drug discoveries and that may include reducing dividend. Hopefully Tesaro will be successful as acquisition.
zicopele
30/1/2019
09:13
Tipped by Telegraph: Questor: "Glaxo’s breakup is a neat solution to its debt problem, so it’s time to buy back in"
tradermichael
30/1/2019
08:49
Fantastic, they said 1 in 3 people will get shingles, massive market. I paid 130 pounds for a shingles vac.GSK double blockbuster on Shringlix I reckon.
montyhedge
30/1/2019
08:38
Glaxo has seen strong growth momentum in its three new products — Trelegy Ellipta, Shingrix and Juluca – so far this year - each could become a blockbuster
tradermichael
30/1/2019
08:32
Demand outstripping supply for shingles vac, what a great problem to have. Already blockbuster could we have double blockbuster coming years for that vaccine.
montyhedge
29/1/2019
18:00
Yes lessons were learnt,good bittersweet memories,no regrets easy come easy go,that's life!
abdullla
29/1/2019
16:41
Same here....I paid for a holiday on a company called eprime financial. Lost on scoot.com and Marconi. Remember John Mayo?
zicopele
29/1/2019
16:39
Yeah, I made and lost a fortune on Scoot.
tradermichael
29/1/2019
16:21
Crikey...Energis is a name from the past. Anyone remember the shill who used to shamelessly pump Sopheon? Those companies went pop in 2001. Scoot.com.is another beauty.
zicopele
29/1/2019
16:04
Abdullla woz with TMF in the late sixties,these were the times of the disgraced Baltimore,Marconi and Energis all now are RIP!
abdullla
29/1/2019
15:40
Long since given up with TMF Their articles are anodyne and generic - its a shame as back in the early days they used to offer some insight and the tips actually did quite well. I did have a few conversations with one of the better authors too.
dr biotech
29/1/2019
14:56
Stupid article - the GSK network of local subsidiaries will ensure minimal impact of any loss of sales on the Continent for currently approved products.
alphorn
29/1/2019
13:59
TMF is run by shysters. One says buy on a share and his colleague advises sell.
zicopele
29/1/2019
13:17
A couple of snippets from TMF: See the recent relation of the share price to results announcements. The price has fallen between 1% and 3.5% on three of the previous four results days in the past year, but has recovered quickly thereafter. As far as Brexit,less than 30% of the companies’ revenues came from Europe in the last quarter, with the rest coming from the US and other international markets, helping to protect it from excessive exposure to a possibly-weaker UK or EU economy.
tradermichael
29/1/2019
12:59
Our next quarterly dividend soon is 23p, dividend on the doormat every 13 weeks, I love GSK, lol.
montyhedge
29/1/2019
12:54
Forward guidance not good.
zicopele
29/1/2019
12:52
They beat on earnings, beat on sales, investors always want more, lol.
montyhedge
Chat Pages: Latest  772  771  770  769  768  767  766  765  764  763  762  761  Older
ADVFN Advertorial
Your Recent History
LSE
GSK
Glaxosmith..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200405 16:50:46